Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 4/20 | 0.34 |
| ▸ | APAF1 | O14727 | 3/20 | 0.34 |
| ▸ | TDP2 | O95551 | 3/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL11422311 | 1.00 | MAPT (0.42) | MAPTHTTSMN1; SMN2TP53STAT3 | |
| Triaziquone SCHEMBL10414999 | 0.98 | MAPT (0.41) | MAPTHTTSMN1; SMN2TP53STAT3 | |
| Triaziquone SCHEMBL11744970 | 0.96 | MAPT (0.40) | MAPTHTTSMN1; SMN2TP53STAT3 | |
| Triaziquone SCHEMBL7564127 | 0.92 | TP53 (0.37) | MAPTHTTSMN1; SMN2TP53STAT3 | |
| Triaziquone SCHEMBL8585531 | 0.92 | HTT (0.37) | MAPTHTTSMN1; SMN2TP53STAT3 | |
| Triaziquone SCHEMBL1241564 | 0.91 | TP53 (0.36) | MAPTHTTSMN1; SMN2TP53STAT3 | |
| Triaziquone SCHEMBL7783197 | 0.90 | MAPT (0.46) | MAPTHTTSMN1; SMN2TP53STAT3 | |
| Triaziquone SCHEMBL2095563 | 0.90 | TP53 (0.38) | MAPTHTTSMN1; SMN2TP53STAT3 | |
| Triaziquone SCHEMBL8507558 | 0.89 | DNMT1 (0.41) | MAPTHTTSMN1; SMN2TP53STAT3 | |
| Triaziquone SCHEMBL9726159 | 0.89 | TP53 (0.37) | MAPTHTTSMN1; SMN2TP53STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6444 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025222268-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING ATROPHIC VAGINITIS | JASTLABS CORPORATION (CA) | 2025-10-30 | — | — | WO | claimed |
| US-12378430-B2 | Ink, manufacturing method of display device using the same, and display device | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-08-05 | — | — | US | claimed |
| CN-120020251-A | Method for extracting metavirus genome DNA in surface sediment | 中国科学院城市环境研究所 | 2025-05-20 | — | — | CN | claimed |
| EP-4553170-A1 | PELLET COMPRISING A SPECIFIC POLYMER SPECIES | midge medical GmbH (DE) | 2025-05-14 | — | — | EP | claimed |
| US-20250064751-A1 | STABLE FORMULATIONS OF LIPID-ENCAPSULATED RNA | GREENLIGHT BIOSCIENCES, INC. | 2025-02-27 | — | — | US | claimed |
| EP-4507722-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | Bluewillow Biologics, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| US-20240400612-A1 | AN IMPROVED PROCESS FOR PURIFICATION OF FUSION PROTEIN | ACQUIOM AGENCY SERVICES, AS COLLATERAL AGENT | 2024-12-05 | — | — | US | claimed |
| CN-118995883-A | Cobalt ion detection reagent, method and application | 清华大学深圳国际研究生院 | 2024-11-22 | — | — | CN | claimed |
| EP-4457824-A1 | COMPUTER IMPLEMENTED METHODS FOR DETECTING ANALYTES IN IMMUNOASSAYS | Invitrogen BioServices India Private Limited (IN) | 2024-11-06 | — | — | EP | claimed |
| US-20240271159-A1 | AAV VECTOR COLUMN PURIFICATION METHODS | SPARK THERAPEUTICS, INC. | 2024-08-15 | — | — | US | claimed |
| WO-2004013351-A2 | TARGET DNA | EPISTEM LIMITED (GB) | 2004-02-12 | — | — | WO | claimed |
| US-20030165855-A1 | Methods for the analysis of non-proteinaceous components using a protease from a bacillus strain | ROCHE MOLECULAR SYSTEMS, INC. | 2003-09-04 | — | — | US | claimed |
| US-20030153735-A1 | Protein purification | GENENTECH, INC. | 2003-08-14 | — | — | US | claimed |
| EP-1201753-A1 | Methods for the analysis of non-proteinaceous components using a protease from a bacillus strain | BOEHRINGER MANNHEIM GMBH (DE) | 2002-05-02 | — | — | EP | claimed |
| US-5879950-A | ADDITION OF PHOSPHATIDYL CHOLINES (LECITHINS) TO CELL-FREE REACTION MIXTURE INCREASES RESTRICTION ENZYME RATE | HELSINKI UNIVERSITY LICENSING LTD. OY (FI) | 1999-03-09 | — | — | US | claimed |
| CN-1174557-A | Keratan sulfate oligosaccharide fraction and pharmaceutical agent containing the same | SEIKAGAKU KOGYO CO LTD (JP) | 1998-02-25 | — | — | CN | claimed |
| EP-0485510-A4 | HIGH GEL STRENGTH AND LOW ELECTROENDOSMOSIS AGAROSE | — | 1992-11-04 | — | — | EP | claimed |
| EP-0485510-A1 | HIGH GEL STRENGTH AND LOW ELECTROENDOSMOSIS AGAROSE | FMC Corporation (US) | 1992-05-20 | — | — | EP | claimed |
| WO-1991001995-A1 | HIGH GEL STRENGTH AND LOW ELECTROENDOSMOSIS AGAROSE | FMC CORPORATION (US) | 1991-02-21 | — | — | WO | claimed |
| US-4983268-A | High speed electrophoresis using purified agarose | FMC CORPORATION (US) | 1991-01-08 | — | — | US | claimed |